Firefly Luciferase K562 Cell Line
Recombinant K562 cells constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2D | BPS Bioscience #79639 |
96-well Tissue Culture-treated White Clear-bottom Assay Plate | Corning #3610 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.
Thaw Medium 2 (BPS Bioscience #60184):
RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.
Growth Medium 2D (BPS Bioscience #79639):
RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 200 μg/ml of Hygromycin B.
The cell line has been screened to confirm the absence of Mycoplasma species.
The K562 cell line was established from a patient with chronic myelogenous leukemia (CML) in terminal blast crisis. The Firefly Luciferase K562 Cell Line does not express antigens CD19, CD20 or CD22, therefore it makes an excellent negative control in assays that measure specific killing by CAR-T cells targeting B cell antigens CD19, CD20, and CD22. It can also be used as a highly sensitive in vitro target for the natural killer assay. The signal generated by the firefly luciferase reporter is proportional to cell numbers.